CD206+ Resident Macrophages: A Candidate Biomarker for Renal Cystic Disease Activity in Preclinical Models and Patients With Autosomal Dominant Polycystic Kidney Disease
Zhang LiKurt A. ZimmermanSreelakshmi CherakaraPhillip ChumleyCourtney J. HaycraftReagan S. AndersenMandy J. CroyleErnald J. AloriaIsis ThomasHanan ChweihKristin L. SimanyiJames F. GeorgeMichal MrugBradley K. Yoder
0
Citation
0
Reference
10
Related Paper
Imaging biomarker
Cite
Citations (54)
Cite
Citations (7)
Cite
Citations (101)
A pathophysiologic model of Alzheimer's disease (AD) has been recently proposed in which beta amyloid accumulation occurs earlier (indexed by abnormal CSF Abeta42), followed by tau-mediated neuronal injury and dysfunction (abnormal CSF tau or FDG-PET) and lastly atrophic changes (abnormal hippocampal volume, HV). The aim of this study is to validate this model by comparing clinical features and conversion to AD and other dementias among groups of patients with mild cognitive impairment (MCI) with different abnormal biomarker profiles. The patients of this study were 58 with MCI in whom AD biomarkers (CSF Abeta42 and tau, temporoparietal hypometabolism on 18F-FDG PET, and hippocampal volume) were collected. Patients were divided into 3 groups of no abnormal biomarker, AD biomarker pattern (including 3 subgroups of early = only abnormal Abeta42, intermediate = abnormal Abeta42 and FDG-PET or tau, and late = abnormal Abeta42, FDG-PET or tau, and HV), and any other biomarker combination. MCI patients with AD biomarker pattern had lower behavioral disturbances than patients with any other biomarker combination (P <.0005) and lower performance on verbal and nonverbal memory than the other two groups (P = .07 and P = .004, respectively). Within the 3 subgroups with AD biomarker pattern there was a significant trend to higher rate of conversion to dementia (p for trend = .006). Moreover, AD was the type of incident dementia in 100% of patients with an AD biomarker pattern, but 0% and 27% in converters with no abnormal biomarker and any other biomarker combination, respectively (P = .002). Clinical cases representative of the three groups were also described. The results of this study provide evidence in favor of the dynamic biomarker model and support the use of biomarkers for the diagnosis of MCI due to AD according to the new recently published research criteria.
Cite
Citations (1)
miRNA-21 is among the most abundant and highly conserved microRNAs (miRNAs) recognized. It is expressed in essentially all cells where it performs vital regulatory roles in health and disease. It is also frequently claimed to be a biomarker of diseases such as cancer and heart disease in bodily-fluid based miRNA studies. Here we dissociate its contributions to cellular physiology and pathology from its potential as a biomarker. We show how it has been claimed as a specific predictive or prognostic biomarker by at least 29 diseases. Thus, it has no specificity to any one disease. As a result, it should not be considered a viable candidate to be a biomarker, despite its continued evaluation as such. This theme of multiple assignments of a miRNA as a biomarker is shared with other common, ubiquitous miRNAs and should be concerning for them as well.
Cite
Citations (171)
Biomarker Discovery
Cite
Citations (0)
Commonly used designs for clinical trials involving biomarkers include targeted design, biomarker‐stratified design (BSD), and biomarker‐guided (strategy) design (BGD). This article gives details of these designs and discusses their strengths and drawbacks. For these designs, efficiency of testing certain treatment parameters can often be improved by enrichment, increasing the proportion of biomarker‐positive patients, especially when the proportion of biomarker positives is low in the underlying patient population. An enriched biomarker‐stratified design (EBSD) enriches the cohort of randomized patients by directly oversampling the relevant patients with the true biomarker based on the biomarker value. When the cost or difficulty of assessing the true biomarker for all patients prior to randomization is high, one can also improve efficiency by oversampling biomarker positives based on a cheaper auxiliary variable or a surrogate biomarker that correlates with the true biomarker, using an auxiliary‐variable‐enriched biomarker‐stratified design (AEBSD). For both enriched designs, we discuss how to choose the optimal enrichment proportion when testing a single hypothesis or two hypotheses simultaneously.
Oversampling
Clinical study design
Cite
Citations (1)
The importance of cardiovascular disease in adults with chronic kidney disease is now well recognized. For children who develop chronic kidney disease, cardiovascular disease is also a leading cause of eventual morbidity and mortality. Although the clinical manifestations of cardiovascular disease may not be apparent until later, early subclinical findings can be observed even during childhood. This review updates the reader on the epidemiology of cardiovascular disease in pediatric chronic kidney disease, discusses risk factors and potential mechanisms of accelerated cardiovascular disease, reviews evidence of early manifestations of cardiovascular disease in pediatric chronic kidney disease, and briefly discusses prevention and treatment strategies.
Subclinical infection
Cite
Citations (11)
Much of precision medicine research today seeks to find a biomarker, or like King Richard, our kingdom might be lost. The hope is that if one is successful in identifying such a biomarker [1], all will be resolved: diagnosis, prognosis and the best treatment regime identified from the morass of treatment options available. In this context, the research for a single, do-all biomarker is a truly dramatic irony because it may not exist, consider the rise and fall of C-reactive protein (CRP) or exhaled nitric oxide fraction ( F eNO). Yet such a biomarker could be quite useful in asthma, a syndrome that so often defies definition. With this mythical biomarker, one could clearly decide whether the patient has asthma, assess how severe the disease is, and even guide selection of which of the many available treatment regimens should be employed. Tantalising evidence purports IL-6 to be a biomarker for adult-onset asthma that predicts ICS use and symptoms
Cite
Citations (33)
Different CSF biomarker combinations can provide conflicting diagnostic information in Alzheimer′s disease (AD). This is often attributed to differences in sensitivity and specificity, at the cohort level, between CSF markers (Aβ42, t-Tau, p-Tau181, t-Tau/Aβ42, and p-Tau181/Aβ42). When these biomarkers are analyzed against the same gold standard independently, conflicting biomarker information can also result from biomarker substructures not obvious to investigators. Previous studies have not examined conflicting biomarker information at the individual level (e.g., a profile showing normal Aβ42 levels but abnormal t-Tau/Aβ42 ratio may be interprted as AD-like even though the normal Aβ42 level argues against amyloid pathology). The prevalence of these conflicts and ways to resolve them are unknown. We measured CSF AD biomarker levels in one consecutive series (n=431) from Emory University using the multiplex AlzBio3 assay and surveyed the concordance rates between CSF biomarkers at the individual level. We also compared these results with those from clinical testing through a comparable ELISA. To resolve the issue of differential sensitivity and biomarker substructure, we then analyzed CSF AD biomarker levels through two-step clustering to identify naturally existing subgroups of biomarker profiles. Finally, to determine if the cluster membership or the combination of independent biomarker information confers greater information on prognosis, we analyzed if either predicted longitudinal cognitive changes in the Alzheimer’s Disease Neuro-Imaging Initiative (ADNI, n=409). Conflicting CSF biomarker information was very common: 59% of the Emory subjects and 37% of ADNI subjects had at least one biomarker providing diagnostic information distinct from the other biomarkers. Clustering analysis revealed three groupings: one characterized by p-Tau181/Aβ42>0.131 and longitudinal cognitive decline in MCI, and two others (including one characterized by Aβ42>258.5pg/mL) associated with cognitive stability. Within each cluster, concordant or discordant biomarker findings did not further distinguish rates of longitudinal cognitive decline. Conflicting information from different CSF AD biomarkers was common. A data-driven strategy accounting for all biomarker combinations identified naturally existing groupings each characterized by similar biochemical and prognostic profiles.
Concordance
Cite
Citations (0)